The Association for the Cannabinoid Industry (ACI) has announced an updated new membership offering to support companies that wish to enter the newly regulated UK consumer cannabinoid market.
The flexible ‘2022 accelerator package’ enables prospective members to navigate the UK regulatory landscape. It provides new members with an end-to-end solution for full market authorisation for their raw material and food products containing legal cannabinoids.
The UK, which has a population of almost 67 million, has the world’s most developed regulatory framework for legal cannabinoids.
This market is estimated to be worth £690 million ($1 billion) by the end of 2021, making it the second largest in the world after the US.
ACI’s membership offering has three core pillars:
First, representing its members at the highest level so their voice is heard and a favourable regulatory environment exists to operate in.
Secondly, it offers cost-effective access to the necessary toxicological data to gain market authorisation in the UK and EU.
Thirdly, it offers technical consultancy where the team of industry experts offers bespoke consultancy solutions.
This membership includes a £6,000 account that can be redeemed for additional services such as bespoke consultancy, sponsorship opportunities and ACI partner services including legal, communications and trading standards.
This account expedites the process of engagement by cutting administration time to ensure our members – that are made up of raw material suppliers, manufacturers, brands and retailers – get the support they need, when they need it.
ACI’s consultants guide companies through the complexities and reduce costs to market by providing the necessary toxicological data to create robust market authorisation dossiers.
It also provides technical and scientific advice to achieve UK and EU regulatory compliance; end-to-end novel foods application consultancy; Business-to-Business marketing, communication services, etc.
The ACI also offered access to licensed toxicological data. This provides companies a cost-efficient way to generate the required toxicological data for legal cannabinoids in companies novel foods applications to the UK’s Food Standards Agency (FSA) and European Food Safety Authority (EFSA).